CSS
FTH

Cubist Systematic Strategies’s Faeth Therapeutics FTH Stock Holding History

Cubist Systematic Strategies’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-640
Closed -$74K – 3752
2021
Q4 		$74K Buy
+640
New +$95.6K ﹤0.01% 3258

Other funds holding FTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cubist Systematic Strategies's FTH Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of Faeth Therapeutics (FTH) in Q1 2022, closing a stake of 640 shares — an estimated $74K sold.

Cubist Systematic Strategies first reported a position in FTH in Q4 2021 and held it in 1 quarter. The position peaked at $74K in Q4 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q1 2022.

  • Cubist Systematic Strategies reported no remaining Faeth Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 640 Faeth Therapeutics shares in Q1 2022, an estimated $74K.
  • Cubist Systematic Strategies first reported a position in Faeth Therapeutics in Q4 2021 and held it in 1 quarter.
  • Cubist Systematic Strategies's Faeth Therapeutics position peaked at $74K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.